2024

<div class="textg" style="text-align: justify; font-weight: lighter; line-height: 1.3em; font-size: 15px; border-radius: 3px; color: #80909a; padding: 10px; background-color: #F4F6F9; margin-bottom: 15px;">
 Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our&nbsp;<a href="https://tokenist.com/terms-of-service/" style="text-decoration:underline;color:#3c7b7b" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">website policy</a>&nbsp;prior to making financial decisions.
</div>
<p class="has-drop-cap">In the latest <a aria-label="quarterly financial disclosure (opens in a new tab)" href="https://www.businesswire.com/news/home/20240328487135/en/Walgreens-Boots-Alliance-Reports-Fiscal-2024-Second-Quarter-Results" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">quarterly financial disclosure</a>, Walgreens Boots Alliance, Inc. (NASDAQ: WBA) reported a significant quarter amidst challenging retail landscapes, showing resilience and adaptability. The company achieved a 6.3 percent increase in sales, reaching $37.1 billion.</p>
<p>This growth, reflecting a 5.7 percent increase on a constant currency basis, was driven by sales enhancements across all segments, underscoring the diverse strength of WBA’s operations. However, the financial landscape was not without its challenges. The company faced a $13.2 billion operating loss, primarily due to a substantial $12.4 billion non-cash impairment charge related to VillageMD goodwill.</p>
<p>This stark contrast to the previous year’s operating income of $197 million underlines the volatile market conditions impacting the healthcare and retail sectors. Despite these hurdles, adjusted operating income stood at $900 million, a 26.5 percent decrease on a constant currency basis. This was partly due to lower sale-leaseback gains and softer U.S. retail performance, partially offset by an uptick in U.S. Healthcare segment profitability.</p>
<h3 id="wba-outperforms-eps-expectations-with-1-20-adjusted-eps">WBA Outperforms EPS Expectations with $1.20 Adjusted EPS</h3>
<p>When juxtaposed with pre-set expectations, WBA’s performance presents a mixed bag. Analysts had projected earnings per share (<a href="https://tokenist.com/investing/how-to-value-a-stock/" rel="noopener noreferrer nofollow" class="deco-link">EPS</a>) of $0.82 and revenue of $35.9 billion for the quarter. WBA outperformed revenue expectations with its $37.1 billion in sales, indicating robust growth and operational success. <br><br>However, the adjusted EPS of $1.20, a 3.4 percent increase that surpasses expectations, is overshadowed by the substantial non-cash impairment charges, leading to a net loss of $5.9 billion for the quarter. This stark discrepancy underscores WBA’s challenges amid its growth trajectory and strategic realignments.</p>
<div class="cta-referral"><img src="https://tokenist.com/wp-content/themes/thetokenist/assets/img/del/cta-referral-1.png" alt="" class="cta-referral__img" loading="lazy" decoding="async">
 <div class="cta-referral__text">
  <p>Join our&nbsp;<a href="https://t.me/thetokenist" target="_blank" rel="noopener noreferrer nofollow" class="deco-link">Telegram group&nbsp;and never miss a breaking story.</a></p>
 </div>
</div>
<h3 id="wba-narrows-fiscal-2024-adj-eps-guidance-to-3-20-to-3-35">WBA Narrows Fiscal 2024 Adj. EPS Guidance to $3.20 to $3.35</h3>
<p>Looking ahead, WBA narrows its fiscal 2024 adjusted EPS guidance to $3.20 to $3.35, reflecting the ongoing challenges in the U.S. retail environment and strategic portfolio adjustments. <br><br>This revised guidance stems from the early wind-down of the sale-leaseback program and lower earnings from share sales of its equity method investee, Cencora, counterbalanced by effective execution in pharmacy services and a favorable adjusted effective tax rate.</p> <iframe src="https://tokenist.substack.com/embed" width="100%" height="320" style="border:1px solid #EEE; background:white;" frameborder="0" scrolling="no"></iframe>
<p><em>Disclaimer: The author does not hold or have a position in any securities discussed in the article.</em></p>
<h3 id="br"><br></h3>
<p>The post <a rel="noopener noreferrer nofollow" href="https://tokenist.com/walgreens-boots-alliance-wba-shows-resilience-in-q2-with-37-1-b-in-sales/">Walgreens Boots Alliance (WBA) Shows Resilience in Q2 with $37.1 B in Sales</a> appeared first on <a rel="noopener noreferrer nofollow" href="https://tokenist.com">Tokenist</a>.</p>

Walgreens Boots Alliance (WBA) Shows Resilience in Q2 with $37.1 B in Sales

Table of Contents

Tokenist

Other articles published on Mar 28, 2024

Ethena Labs announces 750 million ENA airdrop for its community

Larry Fink on Fox Business + SEC vs Ethereum ETF

20 Billion Dollar Cryptocurrency Investigation from USA and UK to Russia!

Dogecoin Soars 17% To Break $0.21 As Volume Explodes

Coinbase CEO Celebrates Court Dismissal of SEC Claim Against Wallet Service

BEFE Coin’s Ascendance: Unveiling the 100X Gem Phenomenon

Join our free newsletter for daily crypto updates!